TY - JOUR
T1 - A Randomized Comparison of Transcervical and Transabdominal Chorionic-Villus Sampling
AU - U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group
AU - Jackson, Laird G.
AU - Zachary, Julia M.
AU - Fowler, Sarah E.
AU - Desnick, Robert J.
AU - Golbus, Mitchell S.
AU - Ledbetter, David H.
AU - Mahoney, Maurice J.
AU - Pergament, Eugene
AU - Simpson, Joe Leigh
AU - Black, Susan
AU - Wapner, Ronald J.
PY - 1992/8/27
Y1 - 1992/8/27
N2 - Chorionic-villus sampling is done in early pregnancy to obtain fetal cells for the prenatal diagnosis of genetic and chromosomal defects. Transcervical chorionic-villus sampling has been shown to be safe and effective in national trials. Recently, an alternative transabdominal technique has been suggested as potentially easier and safer. From April 1987 through September 1989, we prospectively compared transcervical and transabdominal chorionic-villus sampling in 3999 women with singleton pregnancies in whom the risk of a genetically abnormal fetus was increased. Women between 7 and 12 weeks of gestation underwent ultrasonographic evaluation of placental and uterine position. Those with active vaginal infections, active bleeding, or cervical polyps were excluded. If the obstetrician thought either sampling procedure was acceptable, the woman was asked to consent to random assignment to one of the two procedures. Both groups were followed to determine the outcome of pregnancy and the rate of spontaneous fetal loss after chorionic-villus sampling. Among the 3999 women who entered the study, sampling was attempted in 3873 (97 percent), 1944 of whom had been assigned to undergo transcervical sampling and 1929 to undergo transabdominal sampling. Of these 3873 women, sampling was eventually successful in 3863. Sampling was successful after a single insertion of the sampling instrument in 94 percent of the transabdominal procedures and 90 percent of the transcervical procedures. Among the women with cytogenetically normal pregnancies who had sampling because of maternal age, the rate of spontaneous fetal loss through 28 weeks of pregnancy was 2.5 percent in the transcervical-sampling group and 2.3 percent in the transabdominal-sampling group (difference, 0.26 percent; 95 percent confidence interval, -0.5 to 1.0 percent). Transabdominal and transcervical chorionic-villus sampling appear to be equally safe procedures for first-trimester diagnosis of fetal abnormalities. (N Engl J Med 1992;327:594–8.), CHORIONIC-VILLUS sampling retrieves cells from the developing placenta for genetic or chromosomal analysis during the first trimester and has been used clinically since early 1984.1 , 2 The first method, transcervical sampling, was adopted rapidly at many centers in Europe and North America, and it was found to be a safe and efficacious approach to early prenatal diagnosis in several clinical trials.3 4 5 6 Transabdominal sampling was subsequently offered as an alternative technique, with claimed advantages of a lower risk of infection, ease of learning due to its similarity to transabdominal amniocentesis, and overall increased safety because the sampling instrument is a needle that…
AB - Chorionic-villus sampling is done in early pregnancy to obtain fetal cells for the prenatal diagnosis of genetic and chromosomal defects. Transcervical chorionic-villus sampling has been shown to be safe and effective in national trials. Recently, an alternative transabdominal technique has been suggested as potentially easier and safer. From April 1987 through September 1989, we prospectively compared transcervical and transabdominal chorionic-villus sampling in 3999 women with singleton pregnancies in whom the risk of a genetically abnormal fetus was increased. Women between 7 and 12 weeks of gestation underwent ultrasonographic evaluation of placental and uterine position. Those with active vaginal infections, active bleeding, or cervical polyps were excluded. If the obstetrician thought either sampling procedure was acceptable, the woman was asked to consent to random assignment to one of the two procedures. Both groups were followed to determine the outcome of pregnancy and the rate of spontaneous fetal loss after chorionic-villus sampling. Among the 3999 women who entered the study, sampling was attempted in 3873 (97 percent), 1944 of whom had been assigned to undergo transcervical sampling and 1929 to undergo transabdominal sampling. Of these 3873 women, sampling was eventually successful in 3863. Sampling was successful after a single insertion of the sampling instrument in 94 percent of the transabdominal procedures and 90 percent of the transcervical procedures. Among the women with cytogenetically normal pregnancies who had sampling because of maternal age, the rate of spontaneous fetal loss through 28 weeks of pregnancy was 2.5 percent in the transcervical-sampling group and 2.3 percent in the transabdominal-sampling group (difference, 0.26 percent; 95 percent confidence interval, -0.5 to 1.0 percent). Transabdominal and transcervical chorionic-villus sampling appear to be equally safe procedures for first-trimester diagnosis of fetal abnormalities. (N Engl J Med 1992;327:594–8.), CHORIONIC-VILLUS sampling retrieves cells from the developing placenta for genetic or chromosomal analysis during the first trimester and has been used clinically since early 1984.1 , 2 The first method, transcervical sampling, was adopted rapidly at many centers in Europe and North America, and it was found to be a safe and efficacious approach to early prenatal diagnosis in several clinical trials.3 4 5 6 Transabdominal sampling was subsequently offered as an alternative technique, with claimed advantages of a lower risk of infection, ease of learning due to its similarity to transabdominal amniocentesis, and overall increased safety because the sampling instrument is a needle that…
UR - http://www.scopus.com/inward/record.url?scp=0026687711&partnerID=8YFLogxK
U2 - 10.1056/NEJM199208273270903
DO - 10.1056/NEJM199208273270903
M3 - Article
C2 - 1640952
AN - SCOPUS:0026687711
SN - 0028-4793
VL - 327
SP - 594
EP - 598
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 9
ER -